PARIS, April 4, 2011 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the genome engineering specialist, has announced today that it has signed a license agreement with a pharmaceutical company covering certain uses of its homologous recombination technology patents and patent applications, in the oncology therapeutic field.
This agreement has triggered an immediate payment of euro 3M ($4.2M) to Cellectis.
Further details of the arrangement have not been disclosed.
About Cellectis
Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, bioresearch and agriculture. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.
More information at www.cellectis.com
Follow Cellectis on Twitter at www.twitter.com/cellectis.
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
For further information, please contact:
SOURCE Cellectis